뇌전증약을 복용 중인 뇌전증 환자에서 코로나바이러스감염증-19 치료제를 사용할 때 고려사항
Consideration for Coronavirus Disease 2019 Drug Treatment in Patients with Epilepsy on Antiepileptic Drugs
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Several medications are approved to treat coronavirus disease 2019 (COVID-19) in Korea including nirmatrelvir/ritonavir, remdesivir, and regdanvimab. There is potential drug-drug interaction between antiepileptic drugs (AEDs) and the medications used to treat COVID-19. Several AEDs such as phenytoin, carbamazepine, phenobarbital, and primidone are strong cytochrome P450 inducers and can inhibit the drugs used for COVID-19. Particularly, these drugs are contraindicated with nirmatrelvir/ritonavir (Paxlovid® ). There is a weaker drug-drug interaction between the AEDs and remdesivir. No significant interaction has been reported between the AEDs and molnupiravir. Pharmacokinetic interactions of the AEDs are important in effective management of COVID-19 in patients with epilepsy
Abstract
Several medications are approved to treat coronavirus disease 2019 (COVID-19) in Korea including nirmatrelvir/ritonavir, remdesivir, and regdanvimab. There is potential drug-drug interaction between antiepileptic drugs (AEDs) and the medications used to treat COVID-19. Several AEDs such as phenytoin, carbamazepine, phenobarbital, and primidone are strong cytochrome P450 inducers and can inhibit the drugs used for COVID-19. Particularly, these drugs are contraindicated with nirmatrelvir/ritonavir (Paxlovid® ). There is a weaker drug-drug interaction between the AEDs and remdesivir. No significant interaction has been reported between the AEDs and molnupiravir. Pharmacokinetic interactions of the AEDs are important in effective management of COVID-19 in patients with epilepsy
참고문헌 (18)
- Rothan HA, "The epidemiology and pathogenesis of coronavirus disease(COVID-19)outbreak", J Autoimmun, 109, pp.102433~ (2020)
- "FAQs about COVID-19 and epilepsy for clinicians in english"[URL]
- Fırat O, "COVID-19 & antiepileptic drugs : should we pay attention?", Seizure, 80, pp.240~241 (2020)
- "Clinically relevant drug-drug interaction between AEDs and medications used in the treatment of COVID-19 patients"[URL]
- Johannessen SI, "Antiepileptic drug interactions-principles and clinical implications", Curr Neuropharmacol, 8, pp.254~267 (2010)
- "Interactions with experimental COVID-19 therapies"[URL]
- "Paxlovid FDA emergency use authorisation"[URL]
- "Conditions of use, conditions for distribution and patients targeted and conditions for safety monitoring addressed to member states for unauthorised product paxlovid (PF-07321332 150 mg and ritonavir 100 mg)"[URL]
- Patsalos P, "Antiepileptic Drug Interactions: A Clinical Guide" (2013), Springer
- Brodie MJ, "Enzyme induction with antiepileptic drugs : cause for concern?", Epilepsia, 54, pp.11~27 (2013)
- "The time course of de-induction of lamotrigine with carbamazepine and phenytoin"[URL]
- Punyawudho B, "Characterization of the time course of carbamazepine deinduction by an enzyme turnover model", Clin Pharmacokinet, 48, pp.313~320 (2009)
- Benton WW, "Pediatric Critical Care", pp.1569~1589 (2011), Elsevier Saunders
- Humeniuk R, "Safety, tolerability, and pharmacokinetics of remdesivir, an antiviral for treatment of COVID-19, in healthy subjects", Clin Transl Sci, 13, pp.896~906 (2020)
- Yang K, "What do we know about remdesivir drug interactions?", Clin Transl Sci, 13, pp.842~844 (2020)
- Syed YY, "Regdanvimab : first approval", Drugs, 81, pp.2133~2137 (2021)
- "Conditions of use, conditions for distribution and patients targeted and conditions for safety monitoring adressed to member states for unauthorised product regkirona (regdanvimab)"[URL]
- "Conditions of use, conditions for distribution and patients targeted and conditions for safety monitoring adressed to member states for unauthorised product lagevrio (molnupiravir)"[URL]